AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02396628
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
Trial: NCT02280694
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02280694
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02280694
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02280694
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01831479
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single administration of rosuvastatin 20mg tablet QD for 7 consecutive days
Trial: NCT01831479
Drug: Rosuvastatin and olmesartan
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Co-administration of rosuvastatin 20mg tablet and and olmesartan 40mg tablet QD for 7 consecutive days
Trial: NCT02880540
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002888
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02381236
Drug: G-202
RxNorm normalized name: krill/om-3/dha/epa/phospho/ast 500 mg-86 mg-25 mg-40 mg-202 mg-101 mcg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
Trial: NCT02117258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1,000 mg/m\^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
Trial: NCT03095807
Drug: NNC9204-1706 A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
Trial: NCT05718466
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02247557
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (N/S) 50ml in single intravesical instillation
Trial: NCT03095807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin)
Trial: NCT01268163
Drug: European Taxotere®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-100 mg/m\^2 IV
Trial: NCT01268163
Drug: American Taxotere®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60-100 mg/m\^2 IV
Trial: NCT01670370
Drug: R-GemOx
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab Gemcitabine Oxaliplatin
Trial: NCT02142140
Drug: Long-acting stimulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
Trial: NCT03037931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline Solution
Trial: NCT04370548
Drug: DARE-BV1clindamycin phosphate vaginal gel, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One full applicator (5 g) of clindamycin phosphate vaginal gel, 2% (100 mg clindamycin) or placebo gel will be applied intravaginally as a single dose within 1 day of randomization.
Trial: NCT01834547
Drug: caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg
Trial: NCT01834547
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00604786
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing is based on IgE level and weight given every 2 or 4 weeks
Trial: NCT01621737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle placebo
Trial: NCT01516138
Drug: GIK
RxNorm normalized name: Surgikos Tip Cleaner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
Trial: NCT00910689
Drug: Placebo control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03748537
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After resuscitation, hypoperfusion in the sepsis patients will be treated by fluid resuscitation and vasopressor. Some groups of patients may be not responsive to this treatment (MAP \<65 mmHg), administration of steroids to this group will be blindly randomized (treatment and control group). During resuscitation of septic shock patients with fluid resuscitation and vasopressors, some may not respond to treatment (MAP \< 65 mmHg). Patients who have shock refractory to fluid resuscitation and norepinephrine therapy for more than 0.5 mcg/kg/min will be blindly randomized to receive steroid (treatment group) or placebo (control group). Blood samples will be obtained to determine mitochondrial functioning before, at day 1 and day 7 after administration of study medications in both groups.
Trial: NCT01103323
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Trial: NCT03791905
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: chemotherapy drug
Trial: NCT02306876
Drug: PF-06412562 3mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06412562
Trial: NCT02306876
Drug: PF-06412562 15mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06412562
Trial: NCT00910689
Drug: Optimal Acute Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
Trial: NCT01081353
Drug: Acetylsalicylic Acid (Aspirin BAY1019036)
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One tablet of new formula Aspirin under fasting conditions
Trial: NCT00551590
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo PO (placebo control for sitagliptin) for three days
Trial: NCT00551590
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline IV (placebo control for exendin(9-39)) on two consecutive study days
Trial: NCT02900742
Drug: YiQiFang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Trial: NCT03339700
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 80mg/kg, intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 and -2.
Trial: NCT00189488
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02900742
Drug: YangYinFang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
Trial: NCT02900742
Drug: YiQiYangYinFang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
Trial: NCT02900742
Drug: placebo granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
Trial: NCT00197587
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All women received a background of zidovudine from 34 weeks'gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
Trial: NCT01614470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral use, administered twice a day (q12h)
Trial: NCT00491569
Drug: Sarcosine and D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00564460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 8 weeks
Trial: NCT01034176
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no dose, tablet, daily, 30 days
Trial: NCT04362384
Drug: Prednisolone ointment
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endoanal Prednisolone ointment will be prescribed
Trial: NCT01703533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry flavored solution and Water for Injection
Trial: NCT03217591
Drug: IW-1973
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT03217591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT02555371
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
Trial: NCT01277237
Drug: lactose tablet
RxNorm normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: lactose tablet 4g/day
Trial: NCT01349010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet bid. p.o for 8 weeks
Trial: NCT00625248
Drug: Antithrombotics
RxNorm normalized name: Enzymes, antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: With or without or discontinuted use of Antithrombotics
Trial: NCT03563573
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a dose of \~8 mg/kg of a placebo capsule
Trial: NCT00870454
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules twice daily
Trial: NCT03863860
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT01555658
Drug: Unfractioned Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents\>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200-250 s)
Trial: NCT01241422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
Trial: NCT02951312
Drug: Glycopyrrolate Inhalation Solution 25mg
RxNorm normalized name: glycopyrrolate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg oral inhalation via eFlow Nebulizer, once daily
Trial: NCT02951312
Drug: Glycopyrrolate Inhalation Solution 75mg
RxNorm normalized name: glycopyrrolate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 μg oral inhalation via eFlow Nebulizer, once daily
Trial: NCT00798395
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily on Day 1-7
Trial: NCT02951312
Drug: Glycopyrrolate Inhalation Solution 200mg
RxNorm normalized name: glycopyrrolate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg oral inhalation via eFlow Nebulizer, once daily
Trial: NCT02951312
Drug: Glycopyrrolate Inhalation Solution 200mg Jet
RxNorm normalized name: glycopyrrolate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg oral inhalation via inhalation via jet nebulizer, once daily
Trial: NCT02951312
Drug: Glycopyrrolate Inhalation Solution 500mg
RxNorm normalized name: glycopyrrolate Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 μg oral inhalation via eFlow nebulizer, once daily
Trial: NCT02951312
Drug: Glycopyrrolate Inhalation Solution1000mg
RxNorm normalized name: glycopyrrolate Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 μg oral inhalation via eFlow nebulizer, once daily
Trial: NCT02951312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
Trial: NCT00090129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
Trial: NCT01900197
Drug: 10% Iron Isomaltoside 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered according to local routines and product labeling in doses at the doctors discretion
Trial: NCT00423943
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule containing placebo
Trial: NCT01313247
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
Trial: NCT02699086
Drug: PDC-1421 Capsule
RxNorm normalized name: chlorpheniramine maleate / dihydrocodeine bitartrate / phenylephrine hydrochloride Oral Solution [Despec-PDC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Trial: NCT01670955
Drug: Ferrous Sulphate + Folic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
Trial: NCT02716818
Drug: Chronocort®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
Trial: NCT02716818
Drug: standard glucocorticoid therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this arm will continue on their standard hydrocortisone therapy
Trial: NCT00643799
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg oral capsule once daily for 6 months
Trial: NCT01542762
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each hospital will use a LMWH according to their own preferences.~Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily).
Trial: NCT00073918
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00987246
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT00987246
Drug: LAS41005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical
Trial: NCT01119105
Drug: BC-3781
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
Trial: NCT01119105
Drug: BC-3781
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
Trial: NCT00360555
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator
Trial: NCT00739583
Drug: CHG 2% w/v and IPA 70% v/v
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds
Trial: NCT00739583
Drug: Iodophor 0.7% and IPA 74% w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
Trial: NCT00414037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-treatment
Trial: NCT02847325
Drug: AC0058TA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
Trial: NCT02847325
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT00643799
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg oral capsule twice daily for 6 months
Trial: NCT03828747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
Trial: NCT03828747
Drug: [18F]GTP1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Trial: NCT00643799
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched oral placebo for 6 months
Trial: NCT04521569
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If the donor lungs are randomized to the Steen solution arm, the donor lungs will be perfused with placebo at a rate equivalent to the dosage of Regadenoson (1.44 microgram/kg/min), for a minimum of three hours and maximum of four hours, using the same pediatric syringe pump. The infusion will begin within 10 minutes of the start of the EVLP procedure.
Trial: NCT01009853
Drug: Codeine Sulfate
RxNorm normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 mg tablet
Trial: NCT02507076
Drug: isolated limb perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo ILP with melphalan
Trial: NCT00433940
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
Trial: NCT01094808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules
Trial: NCT01441869
Drug: Diabex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release oral tablets, 1000 mg, single dose
Trial: NCT01441869
Drug: Diabex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended release oral tablets, 500 mg, single dose
Trial: NCT02982395
Drug: Nanoxel®M
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical
Trial: NCT00431080
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks